Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2019

Open Access 01-04-2019 | Adenocarcinoma of the Esophagogastric Junction | Thoracic Oncology

High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma

Authors: Gerd Jomrich, MD, Marlene Hollenstein, CM, Max John, CM, Robin Ristl, MSc, Matthias Paireder, MD, Ivan Kristo, MD, Reza Asari, MD, Sebastian F. Schoppmann, MD, FACS

Published in: Annals of Surgical Oncology | Issue 4/2019

Login to get access

Abstract

Background

Elevated mean corpuscular volume (MCV) is associated with a diminished prognosis for various tumor entities. This study aimed to evaluate the association between preoperative serum MCV levels and both overall (OS) and disease-free survival (DFS) for patients with resectable adenocarcinomas of the esophagogastric junction (AEG).

Methods

This study included consecutive patients undergoing surgical resection between 1992 and 2016. Measured preoperative MCV levels were stratified into quintiles and correlated with patients’ survival and clinicopathologic characteristics.

Results

The study analyzed 314 patients with a median OS of 36.8 months and a median DFS of 20.6 months. The multivariate analysis showed that preoperatively elevated MCV is a significant prognostic factor for OS (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.03–1.08; P < 0.001) and DFS (HR, 1.05; 95% CI, 1.03–1.08; P < 0.001). In the subgroup analysis of neoadjuvantly treated and untreated patients, MCV remained an independent prognostic factor for OS (HR, 1.08; 95% CI, 1.04–1.12; P < 0.001) and DFS (HR, 1.07; 95% CI, 1.03–1.12; P < 0.001) in both groups. In the univariate analysis, tumor stage and differentiation, adjuvant chemotherapy, MCV, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were significantly correlated with diminished OS and DFS.

Conclusion

Preoperatively elevated MCV is an independent prognostic factor for patients with adenocarcinomas of the esophagus and the gastroesophageal junction.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.CrossRefPubMed
3.
Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381–7.CrossRefPubMed
4.
Fontana E, Smyth EC, Cunningham D. Esophagogastric adenocarcinoma: is more chemotherapy better? Curr Treat Options Oncol. 2016;17:21.CrossRefPubMed
5.
Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRefPubMed
6.
Brown CS, Gwilliam N, Kyrillos A, et al. Predictors of pathologic upstaging in early esophageal adenocarcinoma: results from the national cancer database. Am J Surg. 2018;216:124–30.CrossRefPubMed
7.
Ayez N, Lalmahomed ZS, van der Pool AE, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011;18:2757–63.CrossRefPubMedPubMedCentral
8.
Nagai H, Yuasa N, Takeuchi E, Miyake H, Yoshioka Y, Miyata K. The mean corpuscular volume as a prognostic factor for colorectal cancer. Surg Today. 2018;48:186–94.CrossRefPubMed
9.
Zheng YZ, Dai SQ, Li W, et al. Prognostic value of preoperative mean corpuscular volume in esophageal squamous cell carcinoma. World J Gastroenterol. 2013;19:2811–7.CrossRefPubMedPubMedCentral
10.
Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165:1424–33.CrossRefPubMed
11.
Hazelton WD, Curtius K, Inadomi JM, et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2015;24:1012–23.CrossRefPubMedPubMedCentral
12.
Wang JH, Luo JY, Dong L, Gong J, Tong M. Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi’an of Northwest China. World J Gastroenterol. 2004;10:1647–51.CrossRefPubMedPubMedCentral
13.
14.
Lubin JH, Cook MB, Pandeya N, et al. The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett’s Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol. 2012;36:306–16.CrossRefPubMedPubMedCentral
15.
Yoon HJ, Kim K, Nam YS, Yun JM, Park M. Mean corpuscular volume levels and all-cause and liver cancer mortality. Clin Chem Lab Med. 2016;54:1247–57.PubMed
16.
Kaferle J SC. Evaluation of macrocytosis. Am Fam Physician. 2009;79:203–8.PubMed
17.
Jung HA, Kim HJ, Maeng CH, et al. Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. Cancer Res Treat. 2015;47:72–7.CrossRefPubMed
18.
Karvellas CJ, Sawyer M, Hamilton M, Mackey JR. Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol. 2004;27:364–8.CrossRefPubMed
19.
Wenzel C, Mader RM, Steger GG, et al. Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. Anticancer Drugs. 2003;14:119–23.CrossRefPubMed
20.
Haslacher H, Szekeres T, Gerner M, et al. The effect of storage temperature fluctuations on the stability of biochemical analytes in blood serum. Clin Chem Lab Med. 2017;55:974–83.CrossRefPubMed
21.
Ruzicka K, Veitl M, Thalhammer-Scherrer R, Schwarzinger I. The new hematology analyzer Sysmex XE-2100: performance evaluation of a novel white blood cell differential technology. Arch Pathol Lab Med. 2001;125:391–6.PubMed
22.
Brigden ML, Page NE, Graydon C. Evaluation of the Sysmex NE-8000 automated hematology analyzer in a high-volume outpatient laboratory. Am J Clin Pathol. 1993;100:618–25.CrossRefPubMed
23.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
24.
Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680–6.CrossRefPubMed
25.
Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9.CrossRefPubMed
26.
Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Physician. 2009;79:203–8.PubMed
27.
Oh RC, Holt SN, Hitchcock K, Hoekzema G. How do you evaluate macrocytosis without anemia? J Fam Pract. 2008;57:548–50.PubMed
28.
Yokoyama A, Yokoyama T, Kumagai Y, et al. Mean corpuscular volume, alcohol flushing, and the predicted risk of squamous cell carcinoma of the esophagus in cancer-free Japanese men. Alcohol Clin Exp Res. 2005;29:1877–83.CrossRefPubMed
29.
Espinosa E, Feliu J, Zamora P, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 1995;12:67–76.CrossRefPubMed
30.
Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14:381–9.CrossRefPubMed
31.
Jomrich G, Hollenstein M, John M, et al. The modified Glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. Oncotarget. 2018;9:6968–76.CrossRefPubMedPubMedCentral
32.
Porath-Furedi A. The mutual effect of hydrogen ion concentration and osmotic pressure on the shape of the human erythrocyte as determined by light scattering and by electronic cell volume measurement. Cytometry. 1983;4:263–7.CrossRefPubMed
33.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–68.CrossRefPubMed
34.
Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245:707–16.CrossRefPubMedPubMedCentral
35.
Anderegg MCJ, van der Sluis PC, Ruurda JP, et al. Preoperative chemoradiotherapy versus perioperative chemotherapy for patients with resectable esophageal or gastroesophageal junction adenocarcinoma. Ann Surg Oncol. 2017;24:2282–90.CrossRefPubMedPubMedCentral
36.
Wright CD, Mathisen DJ, Wain JC, et al. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction. Ann Thorac Surg. 1994;58:1574–8; discussion 1578–9.CrossRefPubMed
Metadata
Title
High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma
Authors
Gerd Jomrich, MD
Marlene Hollenstein, CM
Max John, CM
Robin Ristl, MSc
Matthias Paireder, MD
Ivan Kristo, MD
Reza Asari, MD
Sebastian F. Schoppmann, MD, FACS
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07186-1

Other articles of this Issue 4/2019

Annals of Surgical Oncology 4/2019 Go to the issue

Colorectal Cancer

Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma

Melanoma

The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma

Thoracic Oncology

Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy

Breast Oncology

The Impact of Radiotherapy on Reoperation Rates in Patients Undergoing Mastectomy and Breast Reconstruction

Translational Research and Biomarkers

Is FGFR2 a Suitable Target to Treat Scirrhous-Type Gastric Cancer?

Breast Oncology

Internal Mammary Chain Sentinel Nodes in Early-Stage Breast Cancer Patients: Toward Selective Removal